secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001651308-23-000025
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen relinquishes board appointment right at BeiGene; Hooper remains
---------------------------------------------------------------------

- Amgen gave up its right to designate a director to BeiGene's board under an amendment to the 2019 Share Purchase Agreement.
- Anthony C. Hooper, Amgen's former designee, will continue serving as director on BeiGene's board until his term ends in 2025.
- The amendment was effective January 30, 2023; Amgen cited BeiGene's global growth as the reason for relinquishing the right.
- Amgen invested approximately $2.78 billion in BeiGene in 2019, receiving shares and board appointment rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/0001651308-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/bgne-20230130.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer